Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.

“A new era in genetic testing has arrived,” said Carlos Bustamante, Ph.D., CEO & Co-Founder, Galatea Bio. “StrataRisk PRS empowers clinical genetic labs to deliver more informative reports to ...

Cedric Pobel, MD, covers the PEACE-1 trial of radiotherapy, standard of care, and abiraterone in low-volume metastatic castration-sensitive prostate cancer.

Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in ...

Every woman has a Scumbag Radar that goes off when they get an 'ick' feeling about a guy — even if everyone else is too ...

Only 45.5% of patients completed guideline-concordant surveillance within 30 months after treatment for high-grade cervical ...

"Our findings suggest that, in the condition of negative sentinel lymph nodes, omitting pelvic lymphadenectomy does not ...

Regarding the March 15 front-page article “ Democratic split widens as Senate averts shutdown ”: ...

Research reveals what science actually knows about EMF exposure health effects, separating evidence-based concerns from ...

Triple-negative breast cancer (TNBC) is the most aggressive ... The size, stage, rate of growth, and other characteristics of the tumor determine the kinds of treatment. Treatment may include ...